The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I substance in the United States, meaning the only legal access pathways are through active...
5-MeO-DMT therapy is attracting serious interest from researchers, executives, and people seeking relief from depression, anxiety, and trauma. The compound is potent, fast-acting, and increasingly the subject of clinical investigation. It also carries real risks that...
Ibogaine opioid treatment research has moved significantly forward in 2025 and 2026, with new clinical data, a landmark $50 million Texas state investment, and a federal executive order directing agencies to accelerate review. The evidence shows real potential for...
Last Updated: May 2026 If you’re looking for psychedelic therapy in Washington DC, Maryland, or Virginia (DMV), your clearest option right now is ketamine, which is FDA-cleared and available at licensed clinics across the DMV region. Washington DC has...
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single guided dose can produce meaningful, lasting reductions in PTSD symptoms. The evidence is promising, but also...
